Core Viewpoint - The company, Times Angel (06699), has announced the establishment of a new senior management position, Chief Strategy Officer, to focus on long-term strategic planning and implementation of key projects [1] Group 1: Management Changes - The board has appointed Song Xin, the current executive director, as the Chief Strategy Officer, effective from November 1, 2025 [1] - Following this appointment, Song Xin will no longer serve as the Chief Operating Officer [1] Group 2: Strategic Focus - The Chief Strategy Officer will be responsible for the company's overall long-term strategy, leading innovation direction exploration, and driving collaborative development of invested enterprises [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6699） 承董事會命 時代天使科技有限公司 主席 馮岱先生 香港，2025年10月24日 於本公告日期，董事會包括執行董事胡杰章先生、黃琨先生、宋鑫先生及董莉女 士；非執行董事馮岱先生；獨立非執行董事韓小京先生、石子先生及周浩先生。 自願性公告 高級管理層職務變動 本公告乃由時代天使科技有限公司（「本公司」）董事會（「董事會」）自願作出。 董事會宣佈，本公司將新設立高級管理層職位－首席戰略官（「首席戰略官」），其 主要職責將專注於本公司中長期整體戰略規劃、策略性重點項目實施、領導創新 方向探索及驅動被投企業協同發展。董事會已委任本公司執行董事宋鑫先生（「宋 先生」）擔任本公司首席戰略官，自2025年11月1日起生效。此次委任之後，宋先 生將不再擔任本公司首席運營官。 董事會衷心感謝 ...

Core Points - Angelalign Technology (06699) announced the issuance of 10,400 ordinary shares on October 21, 2025, due to the exercise of stock options under its initial public offering share option plan [1] Summary by Category Company Actions - The company will issue 10,400 ordinary shares as a result of stock option exercises [1] Financial Implications - The issuance of shares may impact the company's share structure and potentially its market valuation [1] Future Outlook - The exercise of stock options indicates employee confidence and alignment with company performance, which could be a positive signal for investors [1]

Core Viewpoint - Angelalign Technology (06699) announced the issuance of 10,400 ordinary shares on October 21, 2025, due to the exercise of stock options under its initial public offering stock option plan [1] Summary by Category - **Company Actions** - The company will issue 10,400 ordinary shares as a result of stock option exercises [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 時代天使科技有限公司 呈交日期： 2025年10月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06699 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股 ...

Core Insights - LuxCreo has completed a new round of financing led by Times Angel, with Index Capital serving as the exclusive financial advisor [1] - A global strategic partnership will be established between Times Angel and LuxCreo to jointly develop next-generation high-performance invisible orthodontic 3D printing materials [1]

Core Insights - LuxCreo has recently completed a new round of financing with investment from Times Angel, establishing a global strategic partnership to develop new 3D printing materials and smart platforms [1][7] - The global orthodontic market is expected to exceed $80 billion by 2030, driven by increasing awareness of oral health and advancements in 3D printing technology [1][2] Company Overview - LuxCreo specializes in polymer 3D printing solutions, integrating advanced 3D printers, AI software, and high-performance materials to provide a complete digital production solution [1] - The company has developed direct 3D printing technology for orthodontic appliances, which enhances precision and customization in dental treatments [2][6] Technology and Innovation - Direct 3D printing technology can improve the manufacturing precision of dental aligners to 96.25%, reducing errors and enhancing fit [2] - The ActiveMemory™ shape memory material allows for customized designs and adjustments, improving patient comfort and treatment effectiveness [6][7] Market Dynamics - The dental sector contributes over 70% of LuxCreo's revenue, with more than 80% of its income coming from overseas markets, primarily in Europe and the U.S. [6] - The shift from traditional manufacturing to digital production in the dental industry is seen as a disruptive trend, with increasing recognition of direct 3D printing technology among dental professionals [7]

Core Viewpoint - JPMorgan Chase & Co. has increased its stake in Times Angel (06699.HK) by acquiring an additional 143,800 shares at an average price of HKD 61.5269 per share, raising its ownership percentage from 13.98% to 14.07% [1] Group 1 - On October 10, 2025, JPMorgan Chase & Co. purchased 143,800 shares of Times Angel, amounting to approximately HKD 8.8476 million [1] - Following this transaction, JPMorgan Chase & Co. now holds a total of 24,032,210 shares in Times Angel [1] - The increase in shareholding reflects a strategic investment decision by JPMorgan Chase & Co. in Times Angel [1]

Group 1 - Morgan Stanley increased its stake in Times Angel (06699) by 143,800 shares at a price of HKD 61.5269 per share, totaling approximately HKD 8.8476 million [1] - After the increase, Morgan Stanley's total shareholding in Times Angel is approximately 24.0322 million shares, representing a stake of 14.07% [1]

Core Viewpoint - The company reported significant growth in overseas invisible aligner revenue, reaching approximately $71.7 million in H1 2025, a year-on-year increase of 123.4%, with case numbers surpassing domestic figures for the first time [1][2][5] Financial Performance - In H1 2025, the company achieved total revenue of $161 million, a 33.1% increase year-on-year, with adjusted net profit of $19.49 million, up 84.8% [1][3] - The net profit reached $14.17 million, reflecting a 583.6% increase, while the parent net profit was $14.64 million, a 362.7% rise [1][3] - The overall gross margin stood at 62.4%, consistent with the previous year, while the net margin improved by 7.1 percentage points to 8.8% [1][3] Regional Performance - The domestic market generated revenue of $89.7 million, showing a slight growth of 0.7%, with case numbers increasing by 14.0% to 108.6 thousand [2][3] - The overseas market's case numbers reached 117.2 thousand, a 103.5% increase, marking the first time it exceeded domestic case numbers [2][5] Product Performance - Revenue from invisible aligner solutions in mainland China was $86.23 million, a 2.1% increase, with case numbers growing by 14.0% [3] - Revenue from sales of invisible aligners outside mainland China was $70.99 million, a 122.3% increase, with case numbers also rising by 103.5% [3] Operational Efficiency - The company reported a significant reduction in operating losses in the overseas segment, from $16.7 million to $5.4 million, attributed to business scale expansion and delayed operational plans [1][2] - Sales and marketing expenses increased by 11.3% to $53.76 million, while the sales expense ratio decreased from 39.8% to 33.3% [3] Cash Position - As of June 30, 2025, the company had cash and cash equivalents totaling $344 million, with interest income and investment returns contributing $8.8 million to profits [4] Strategic Outlook - The company is focusing on expanding its international market presence, with plans to increase investments in sales, marketing, clinical support, and overseas production bases [7] - The global orthodontic market presents significant growth opportunities, with the company positioned as the second-largest provider of invisible aligners globally [4][5]